Use the labels in the right column to find what you want. Or you can go thru them one by one, there are only 33,831 posts. Searching is done in the search box in upper left corner. I blog on anything to do with stroke. DO NOT DO ANYTHING SUGGESTED HERE AS I AM NOT MEDICALLY TRAINED, YOUR DOCTOR IS, LISTEN TO THEM. BUT I BET THEY DON'T KNOW HOW TO GET YOU 100% RECOVERED. I DON'T EITHER BUT HAVE PLENTY OF QUESTIONS FOR YOUR DOCTOR TO ANSWER.
Changing stroke rehab and research worldwide now.Time is Brain!trillions and trillions of neuronsthatDIEeach day because there areNOeffective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.
What this blog is for:
My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.
Showing posts with label docosahexaenoic acid. Show all posts
Showing posts with label docosahexaenoic acid. Show all posts
Launching Bneuron - A Breakthrough Dairy Supplement For Brain Protection
SEOUL, South Korea, March 8, 2024 /PRNewswire/ -- Bneuron milk, a breakthrough product in the health and wellness industry, has been entering South Korea
diary market. The product is scientifically proven to offer multiple
benefits for the brain and nervous system. By delivering essential
nutrients that prevent and treat stroke and vestibular disorders[1], Bneuron milk helps consumers improve their cognitive functions, sleep quality, and overall well-being[2]. Bneuron milk is the "golden" solution for a healthier and happier life.
Bneuron
applies "Ultrasound Assisted Extraction" - an ultrasound technology
with the ability to enhance the effectiveness of nutritional active
ingredients in milk by using strong ultrasound waves that can penetrate
deeply into cell membranes. This method keeps the biological activity of
active ingredients at temperatures lower than 70 degrees Celsius, which
can prevent loss and evaporation and also increase the recovery rate of
active ingredients compared to traditional methods.
To
apply this advanced technology to the mass production process, the
company has equipped an advanced and modern production line that fully
meets GMP and FDA standards. The high-capacity machinery and
infrastructure system is operated and controlled by a team of
experienced nutritionists along with leading technical experts in the
industry. From importing raw materials to packaging, Bneuron carries out
strict control to ensure that each product that comes to the user has
the best quality according to prescribed standards.
Bneuron - The "golden" solution to protect the brain and prevent strokes
According
to the latest report of the World Stroke Organization published in the
journal The Lancet Neurology, it is forecast that the death rate due to
stroke will reach 9.7 million cases by 2050.
The prevalence of
stroke is increasing significantly in young and middle-aged people
(<55 years old) around the globe. In particular, the stroke rate in
young people increases on average by about 2% each year, with men four
times higher than women.
Bneuron milk uses advanced technology and
imports from the United States and is a specialized source of nutrition
suitable for adults that can improve the brain, support the treatment
of vestibular diseases, and prevent strokes effectively. The product
contains a list of rare and nutritious ingredients, such as Pasionflower
Extract, Levagen+, Lactium, and colostrum. Moreover, there are other
ingredients such as DHA, whey protein, walnut powder, and almond powder,
enhance stroke resistance better than conventional synthesized products[3].
In
addition, Bneuron also supports nutritional supplementation, health
improvement, and increased resistance; reduces anxiety and stress,
balances sleep. [4]Furthermore, Bneuron milk contains very
little sugar and fat, so it is very suitable for people with a medical
history of diabetes.
Bneuron
is a dairy product for adults and the elderly that can improve overall
health. It is considered by experts to be 10 times more effective in
preventing stroke than conventional synthetic products.
The
product is a combination of leading US technology: "Ultrasound Assisted
Extraction" and rare nutritional ingredients such as Passionflower
Extract and Lactinum.
The answer to that question is becoming clearer, thanks to new research.
Some 10% of American adults regularly take an omega-3 supplement,
despite uncertainty about whether these products truly live up to their
health claims. But two new studies published in November 2018 shed some
light on who might benefit from omega-3 supplements — and who probably
won't.
VITAL
The first study was the Vitamin D and Omega-3 Trial (VITAL), a large
multiyear study with 25,871 healthy adults with no history of
cardiovascular (heart or blood vessel–related) disease and at "usual
risk" for it. The group was racially diverse and chosen to be
representative of the general population, says the study's lead author
Dr. JoAnn E. Manson, professor of medicine and the Michael and Lee Bell
Professor of Women's Health at Harvard Medical School.
Researchers tested, among other things, whether a moderate dosage (1
gram a day) of an omega-3 supplement could help prevent major
cardiovascular events, compared with a placebo. Cardiovascular events
included not only heart attacks, but stroke, and angioplasty procedures
to clear blocked arteries.(Oh god, completely out-of-date.
"The findings are somewhat complex and nuanced. It's not a simple
yes, or no, or one-size-fits-all answer. Some groups tended to benefit,
while other groups didn't," says Dr. Manson.
Although a daily 1-gram omega-3 supplement did not significantly
reduce major cardiovascular events over all, there was a 28% reduction
in heart attacks and promising signals for other heart-related
endpoints, she says. While the supplement didn't seem to protect most
healthy people against future heart problems, certain groups did appear
to benefit, particularly people who ate less than 1.5 servings of fish a
week or didn't eat fish at all. "For these people, there was a
significant 19% reduction in the primary endpoint of major
cardiovascular events, with a 40% reduction in heart attacks," says Dr.
Manson.
The supplements also appeared to benefit African American
participants, who saw a 77% reduction in heart attack for those
receiving the omega-3 supplement, compared with those taking the
placebo, says Dr. Manson. It's unclear why this group benefited more,
and additional studies are needed to confirm the finding.
REDUCE-IT
The second study, called the Reduction of Cardiovascular Events with
EPA–Intervention Trial (REDUCE-IT), included more than 8,000 middle-aged
and older adults who had elevated triglyceride levels and who had
already experienced a cardiovascular event or had other significant risk
factors for one. It aimed to find out if a daily high-dose, 4-gram
prescription omega-3 medication could protect participants against
future cardiovascular events, compared with a placebo. This trial, led
by Dr. Deepak Bhatt, a cardiologist and professor of medicine at Harvard
Medical School, found a substantial 25% reduction in the risk of dying
from heart disease or suffering a cardiovascular event among people who
took the medication, compared with those who had the placebo.
High doses of omega-3 supplements, like the high-dose omega-3 product
used in this trial, aren't appropriate for everyone because they pose
risks, such as bleeding or an increase in a type of abnormal heart
rhythm known as atrial fibrillation, says Dr. Manson. "However, while
high doses are associated with some risk, overall benefits of the
high-dose omega-3 product used in the trial appeared to outweigh the
risks for people with high triglyceride levels and a history of, or at
high risk of, cardiovascular disease," says Dr. Manson.
Choosing the right supplement
Looking for an over-the-counter omega-3 supplement? Here's what to look for:
A 1-gram dose, unless your doctor recommends more.
A combination of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Each of these fatty acids provides different health benefits.
A quality supplement. Good quality indicators are seals from U.S. Pharmacopeia, NSF International, or ConsumerLab.com.
If your triglyceride levels are abnormally high and you have an
elevated risk for cardiovascular disease, talk to your doctor about
whether a high-dose omega-3 prescription might be an option.
Putting the findings into practice
So, what do these findings mean for you? People in good health. If you're healthy and at low
or average risk for heart disease, chances are you don't need an omega-3
supplement, provided you eat fish often, says Dr. Manson. You should eat at least two servings a week of fatty fish,
such as salmon, tuna, or herring. Aim for fish that are high in two
different omega-3 fatty acids, eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), each of which provides unique health
benefits.
Getting your omega-3 fatty acids from food is always preferable to a
supplement. Not only do you get the marine omega-3 fatty acids from the
fish, but you also potentially replace less healthful foods in your
diet, such as red meat, processed foods, or refined grains, says Dr.
Manson. "It's a good lifestyle change to make and has been a
recommendation for a while. Nothing in these studies supersedes the
recommendation for moderate fish intake," she says. Non–fish eaters and African Americans. However, if
you can't eat fish or don't like fish, an omega-3 supplement is
something to consider. (Algae-based supplements are an option if you are
a vegetarian or allergic to fish.) African Americans might also
consider a supplement because of the unique benefits revealed in this
trial.
For these two groups, a daily 1-gram supplement could provide a good
balance between safety and efficacy. "Talk to your health care provider
about whether you're a candidate for a supplement," says Dr. Manson. Already taking omega-3s? If you're already taking an
over-the-counter omega-3 supplement, you don't necessarily need to stop
taking it if you don't fall into one of the categories above, unless
your doctor tells you to. But if you're not taking an omega-3
supplement, whether you should start really depends on your individual
risk factors, says Dr. Manson.
Regardless of whether you opt for an omega-3 supplement, you should
always strive to maintain a healthy diet and lifestyle. "No dietary
supplement is a substitute. We already know that, and I think this is an
important point to reinforce," says Dr. Manson. "Healthy lifestyle
practices, including regular physical activity, healthy diet, and not
smoking, will reduce heart disease risk by close to 80%, and that's
really the main recommendation for heart health," she says. Cardiovascular risk factors. If you have an elevated
triglyceride level and a history of cardiovascular disease or have
major risk factors for it, a high-dose omega-3 medication may be
advisable. This is true even if you're already taking a statin
medication. The omega-3 drug does not replace the statin.
Fast facts about the two trials
The Vitamin D and Omega-3 trial (VITAL)
This study was published online Nov. 10, 2018, by The New England Journal of Medicine. Funding source: The U.S. National Institutes of Health. Who: 25,871 healthy, racially diverse individuals, including 12,786 men ages 50 and older and 13,085 women ages 55 and older. What: A daily 1-gram omega-3 prescription supplement
that included a combination of two omega-3 fatty acids,
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). A 1-gram
dose was chosen because it is a moderate amount that is unlikely to
produce side effects. A control group took a placebo. Key takeaways:
Omega-3 supplements likely won't benefit people who eat at least 1.5 servings of fish per week.
Omega-3 supplements may benefit people with low fish consumption or those with African American heritage.
The Reduction of Cardiovascular Events with EPA–Intervention Trial (REDUCE-IT)
This study was published online Nov. 10, 2018, by The New England Journal of Medicine. Funding source: Amarin, Inc., the company that makes the prescription-strength medication used in the study. Who: 8,179 middle-aged men and women who had high
triglyceride levels and risk factors for heart disease or had already
experienced a heart attack, stroke, or cardiovascular event. Risk
factors included conditions such as high blood pressure and diabetes.
Everyone in the trial was taking a statin to reduce high cholesterol. What: A daily high-dose, 4-gram prescription omega-3
medication or a placebo. Unlike over-the-counter omega-3s, the
medication included EPA only. Key takeaways: This medication may help to protect
high-risk individuals from cardiovascular events. Those taking it were
25% less likely to die from heart disease or to have a heart attack,
stroke, or a type of chest pain called angina. They were also less
likely to need a procedure to open a blocked heart artery. If you have a
high triglyceride level and have had a heart attack or stroke or have
risk factors for cardiovascular disease, you might benefit from taking
the high-dose omega-3 product.
You don't want another stroke so have your doctor create a diet protocol for this. You need to know EXACT amounts per body weight and sex. No guessing allowed.
In this investigation, researchers
tested the premise that total marine n-3 polyunsaturated fatty acids
(PUFA), especially eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) in diet and adipose tissue (biomarkers of long-term intake and
endogenous exposure), are inversely linked to ischemic stroke risk and
its subtypes. Study participants included 57,053 enrollees of the Diet,
Cancer and Health cohort (aged 50-65 years). A full 1,879 participants
had an ischemic stroke during 13.5 years of follow-up. Apart from
cardioembolism, EPA was associated with lower risks of most types of
ischemic stroke, whereas inconsistent findings were observed for total
marine n-3 PUFA and DHA. The EPA content in adipose tissue was inversely
linked to small-vessel occlusion.
Useless without giving us protocol amounts per weight and sex. And we have to figure out what EPA and DHA are. Why the fuck was this research done if not to accomplish helping those at risk for stroke? Damn it all, not your job?
We
hypothesized that total marine n-3 polyunsaturated fatty acids (PUFA),
in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)
in the diet and in adipose tissue (biomarkers of long-term intake and
endogenous exposure) were inversely associated with the risk of ischemic
stroke and its subtypes.
Methods—
The
Diet, Cancer and Health cohort consisted of 57 053 participants aged 50
to 65 years at enrolment. All participants filled in a food frequency
questionnaire and had an adipose tissue biopsy taken at baseline.
Information on ischemic stroke during follow-up was obtained from The
Danish National Patient Register, and all cases were validated. Cases
and a random sample of 3203 subjects from the whole cohort had their
fatty acid composition of adipose tissue determined by gas
chromatography.
Results—
During
13.5 years of follow-up 1879 participants developed an ischemic stroke.
Adipose tissue content of EPA was inversely associated with total
ischemic stroke (hazard ratio [HR], 0.74; 95% CI, 0.62–0.88) when
comparing the highest with the lowest quartile. Also, lower rates of
large artery atherosclerosis were seen with higher intakes of total
marine n-3 PUFA (HR, 0.69; 95% CI, 0.50–0.95), EPA (HR, 0.66; 95% CI,
0.48–0.91) and DHA (HR, 0.72; 95% CI, 0.53–0.99), and higher adipose
tissue content of EPA (HR, 0.52; 95% CI, 0.36–0.76). Higher rates of
cardioembolism were seen with higher intakes of total marine n-3 PUFA
(HR, 2.50; 95% CI, 1.38–4.53) and DHA (HR, 2.12; 95% CI, 1.21–3.69) as
well as with higher adipose tissue content of total marine n-3 PUFA (HR,
2.63; 95% CI, 1.33–5.19) and DHA (HR, 2.00; 95% CI, 1.04–3.84). The EPA
content in adipose tissue was inversely associated with small-vessel
occlusion (HR, 0.69; 95% CI, 0.55–0.88).
Conclusions—
EPA
was associated with lower risks of most types of ischemic stroke, apart
from cardioembolism, while inconsistent findings were observed for
total marine n-3 PUFA and DHA.
Correspondence
to Stine Krogh Venø, MD, Department of Cardiology, Aalborg University
Hospital, Søndre Skovvej 15, 9000 Aalborg, Denmark. Email s.venoe@rn.dk
These always seem to need more followup to be useful rather than doing it
right in the first place and doing some real research. Regardless, I
bet your doctor does nothing with this information. A. Because s/he never read it. B. Because s/he could not be bothered to understand how to implement it in a protocol. C. It is not my job. I am waiting for SOMEONE ELSE TO SOLVE THE PROBLEM. Namely 100% recovery for all my stroke patients.
Introduction:
Ischemic injury induces neurogenesis in the subventricular zone (SVZ)
of the lateral ventricles and subgranular zone (SGZ) of dentate gyrus
(DG), and it promotes the migration of neuroblasts, guided by blood
vessels, into the ischemic damaged area. Recently, we have shown that
docosahexaenoic acid (DHA; 22:6n-3) therapy improves functional and
histological outcomes following experimental stroke. The objective,
hence, is to determine whether DHA administration enhances endogenous
neurogenesis after cerebral ischemia.
Methods:
Twenty-one male SD rats were anesthetized with isoflurane and subjected
to 2 h of middle cerebral artery occlusion (MCAo) by intraluminal
filament. DHA (5 mg/kg, n=10) or saline (n=11) was administered
intravenously at 3 h after onset of MCAo (n = 7-10 per group). BrdU was
injected on days 4, 5 and 6. DCX (doublecortin), NeuN (a marker for
mature neurons), ki-67 (marker for cell proliferation) have been used to
test the proliferation, migration and differentiation of neural
precursor cells. Behavioral tests were conducted on days 1, 2 and 3 and
weeks 1 and 2. Immunohistochemistry with BrdU and ki-67, DCX or NeuN,
and histopathology were performed on day 14.
Results:
DHA-treated animals showed improved neurologic scores compared to the
saline group during the two-week survival period. Total, cortical and
subcortical infarct areas in the DHA-treated group were significantly
attenuated at multiple bregma levels as well as total, cortical and
subcortical infarct volumes by 42.4 %, by 47.5 %, and by 31.2 % compared
to the vehicle-treated group. The number of BrdU+/ki-67+
cells in DHA-treated rats was increased in cortex by 88 %, SVZ by 40 %
and DG by 270 % compared to saline-treated rats. DHA treatment increased
the number of BrdU+/DCX+ cells in the cortex by
65 %, the SVZ by 29 % and the DG (by 58 %) compared to saline-treated
group. In addition, the numbers of BrdU+/NeuN+ cells were increased in the cortex by 49 %, SVZ by 28 % and DG by 48% compared to vehicle treatment.
Conclusion:
DHA increased neurogenesis by proliferation, differentiation and
migration of neural stem cells in the DG, SVZ and peri-infarct area two
weeks after ischemic stroke. In addition, DHA promoted neurobehavioral
recovery and reduced infarct volume.
I really hate these literature searches and meta-analysis, they always seem to need more followup to be useful rather than doing it right in the first place and doing some real research. Regardless, I bet your doctor does nothing with this information. I assume higher CHD risk pretty much correlates to higher stroke risk, to be confirmed with your doctor. A. Because s/he never read it. B. Because s/he could not be bothered to understand how to implement it in a protocol. C. It is not my job. I am waiting for SOMEONE ELSE TO SOLVE THE PROBLEM.
Mayo Clinic Proceedings, 01/17/2017 Alexander DD, et al.
The
target of this study was to assess the impact of eicosapentaenoic and
docosahexaenoic acid (EPA+DHA) on coronary heart disease (CHD), and to
lead meta–analyses of prospective cohort studies to estimate the
association between EPA+DHA consumption and CHD risk. Outcomes show that
EPA+DHA might be connected with lessening CHD risk, with a greater
benefit found among higher–risk populations in RCTs.
Methods
For this study they design a systematic literature search. From
January 1, 1947, to November 2, 2015 they search Ovid/Medline, PubMed,
Embase, and the Cochrane Library, 18 RCTs and 16 prospective cohort
studies examining EPA+DHA from foods or supplements and CHD, including
myocardial infarction, sudden cardiac death, coronary death, and angina,
were recognized.
Random–effects meta–analysis models were utilized to generate summary relative risk estimates (SRREs) and 95% CIs.
Heterogeneity was analyzed in subgroup and sensitivity examinations and by meta–regression.
Dose–response was assessed in stratified dose or consumption investigations.
Publication bias evaluations were performed.
Results
Among RCTs, there was a nonstatistically significant decrease in
CHD risk with EPA+DHA provision (SRRE=0.94; 95% CI, 0.85–1.05).
Subgroup examinations of information from RCTs demonstrated a
statistically significant CHD risk decrease with EPA+DHA provision among
higher–risk populations, including participants with elevated
triglyceride levels (SRRE=0.84; 95% CI, 0.72–0.98) and elevated
low–density lipoprotein cholesterol (SRRE=0.86; 95% CI, 0.76–0.98).
Meta–analysis of information from prospective cohort studies
resulted in a statistically significant SRRE of 0.82 (95% CI, 0.74–0.92)
for higher consumptions of EPA+DHA and risk of any CHD event.
Translational Stroke Research, 10/14/2016Jiang X, et al.
Researchers,
in this present study, report a post–stroke omega–3 polyunsaturated
fatty acid (n–3 PUFA) therapeutic regimen that not only confers
protection against neuronal loss in the gray matter but also promotes
white matter integrity. As per the outcomes the post–stroke
docosahexaenoic acid (DHA) injections in combination with fish oil (FO)
dietary supplement benefit white matter restoration and microglial
responses, thereby dictating long–term functional improvements.
Results from a recent study published in the Journal of Alzheimer's Disease
support the cognitive benefits of DHA, which have been consistently
demonstrated with doses of 900 mg/day or greater. The study, which took
place in Tianjin, China, was a randomized, double-blind,
placebo-controlled trial in 240 (219 completed) Chinese individuals aged
65 and older with mild cognitive impairment. The participants received
either 2g/day of DHA or a corn oil placebo for 12 months and specific
measures of cognitive function were measured at baseline, six months and
12 months.
The study results showed that there was a significant difference in
the Full-Scale Intelligence Quotient (IQ) in the DHA group versus
placebo, with IQ in the DHA group measuring 10% higher than the placebo
group. Additionally, there were statistically significant increases in
two IQ sub-tests (Information and Digit Span). The Information and Digit
Span Subdomains are considered indicators of long-term and short-term
memory, respectively. The findings suggest that DHA supplementation of
2g/day for 12 months in MCI subjects can significantly improve cognitive
function.
While additional larger longer-term studies are needed to confirm the
results, this paper adds to the body of science supporting DHA omega-3s
and their role in supporting cognitive function.
No self-medication. This is for your doctor to read and determine if anything here is useful for you. And I'd be willing to bet you won't hear about this from him/her before you point it out to them. http://www.sciencedirect.com/science/article/pii/S0308814612016561
Abstract
Fish
oil during early postnatal period may modulate the impact of oxidative
stress in the developing brain and thus improve memory and cognitive
behavior. This study investigated the impacts of docosahexaenoic acid
(DHA, C22:6, n-3) and/or phosphatidylserine (PS) on antioxidant
activities in vitro, and the beneficial effects of feeding with
DHA and/or PS on antioxidant activities in brain and liver tissues and
on the cognitive functions of the developing brain. Results indicated
that DHA and/or PS significantly enhanced antioxidant activities and
increased cell viabilities in vitro. Feeding with DHA and/or PS
supplementation not only significantly improved escape latency of
animals, but it also improved the oxidative parameters in the brain,
enhanced glutathione peroxidase activity as well as reduced nitric
mono-oxide levels in the liver. DHA and PS may serve to protect cells
from oxidative stress and further improve learning and memory ability in vivo.
